Option chain shows key data for Innate Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Innate Pharma.

Innate Pharma (NASDAQ:IPHA) Stock, Option Chain

INNATE PHARMA SA-SPONS ADR

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Gentilly,,France,,March,21,,2021:,Sign,And,Logo,On,The

Biotech

Earnings

Large Cap

News

Guidance

Health Care

General

IPHA

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Recent Gains

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

AKTS

ATCH

BTCT

EWTX

FUFU

KPTI

KTOS

LAES

PRTC

RDZN

SGMT

SIDU

SMCI

STEC

TNXP

UBXG

XXII

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

Press Releases

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

Innate Pharma Announces €15M Investment by Sanofi

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

Innate Pharma announces conference call and webcast for Q1 2025 business update

AUTL

PARIS:IPH

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Anika Therapeutics

Astria Therapeutics

Candel Therapeutics

Cidara Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Foghorn Therapeutics

Genfit

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neurogene

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Solid Biosciences

Acelyrin

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

HC Wainwright & Co.

SVB Leerink

Citigroup

Comments

Innate Pharma

Innate Pharma (IPHA) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell